Compound reference
Epitalon
Also known as Epithalon, AEDG
Epitalon (AEDG) is a synthetic pineal tetrapeptide marketed as a telomerase "anti-aging" peptide. The telomerase mechanism has genuine cell-culture support, including one independent replication — but the human evidence is thin, old, non-randomized, and mostly for the predecessor extract, not the peptide itself.
- CAS
- 307297-39-8
- Formula
- C₁₄H₂₂N₄O₉
- Molar mass
- ≈390.4 g/mol
- Sequence
- Ala-Glu-Asp-Gly (AEDG), linear tetrapeptide
Research/regional peptide; not FDA-approved as a drug in the United States.
Mode of action
Epitalon is a synthetic tetrapeptide, alanyl-glutamyl-aspartyl-glycine (Ala-Glu-Asp-Gly, often abbreviated AEDG). It was designed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology as a defined stand-in for Epithalamin — a peptide extract of the bovine pineal gland that the same group had studied since the 1980s. Keeping the two apart matters: much of the "Epitalon" human evidence is actually evidence for the older extract.
Two mechanisms are proposed, and both come largely from the same research tradition. The headline one is telomerase activation: in cultured human somatic cells, Epitalon was reported to switch on expression of the telomerase catalytic subunit (hTERT), restore telomerase activity, and lengthen telomeres — the molecular basis for the "anti-aging" framing. The second is pineal and epigenetic regulation: restoring melatonin rhythm, and Khavinson's broader model in which short peptides enter the nucleus and bind DNA or histones in a sequence-specific way to modulate gene expression. That gene-binding model is mechanistically bold and not independently established; the telomerase piece is the better-supported of the two, and notably it now has a measure of outside confirmation.
Main intended effect
Geroprotection — extending cellular and organismal lifespan, restoring pineal (melatonin) function and circadian rhythm, and slowing age-related physiological decline.
Areas of interest
The dominant framing is longevity and anti-aging, anchored on telomere biology. Adjacent strands include pineal/melatonin and circadian regulation, retinal degeneration (retinitis pigmentosa), and anti-tumor effects in animals. In the consumer market Epitalon is sold specifically as a "telomerase" longevity peptide, typically as a lyophilized powder for reconstitution.
Evidence for intended effects
The mechanism has more independent support than most Khavinson peptides. The original telomerase-induction work in human cells (Khavinson, 2003) was a single-group, cell-culture result — but a 2025 study from an unaffiliated UK group reproduced telomere extension across several human cell lines. That replication carries an important asterisk: in normal cells the effect ran through hTERT/telomerase, but in cancer cell lines telomeres lengthened mainly via alternative lengthening of telomeres (ALT) — a reminder that "turning on telomere maintenance" is not unambiguously benign.
Animal data are broad but almost entirely from the originating network: lifespan extension and reduced spontaneous tumors in HER-2/neu and other mice (and in Drosophila), plus restored melatonin rhythms in aged animals. The human evidence is the weak link. The most-cited "human" result is for Epithalamin, the extract — a 266-person, multi-year, non-randomized study reporting roughly 1.6–1.8-fold lower mortality — not the synthetic peptide. For Epitalon itself, the human data amount to an uncontrolled clinical series in retinitis pigmentosa (a reported ~90% response). These reports are old, single-group, unblinded, and often published in low-impact or Russian-language venues. Independent reviews of the field place Epitalon squarely in the "promising preclinical, limited clinical, no long-term safety data" category.
| Strand | What exists | Tier |
|---|---|---|
| Telomerase / telomere | Original human-cell study + one independent 2025 replication | Cell culture (replicated) |
| Animal lifespan / anti-tumor | Mice, Drosophila; melatonin-rhythm restoration | Preclinical (single-group) |
| Human — Epithalamin extract | 266-person non-randomized mortality study | Low-quality human (extract, not peptide) |
| Human — synthetic Epitalon | Uncontrolled retinitis pigmentosa series | Preliminary / uncontrolled |
Studied amounts (literature dosing context)
Animal studies typically used about 1 µg per mouse (roughly 30–40 µg/kg) subcutaneously, given in monthly courses. The human Epithalamin protocol used 10 mg intramuscularly, five injections at three-day intervals, repeated every six months for three years — but that is the extract. For the synthetic peptide, the originating group has cited a course dose on the order of 0.1 mg as equivalent to a much larger dose of the extract. These are study and extract figures from investigational and non-randomized work; there is no approved human dose for Epitalon, and this page does not provide dosing guidance.
Safety and regulatory status
The Khavinson literature repeatedly describes Epitalon and Epithalamin as free of side effects, and presents that as an advantage of peptide bioregulators. That claim should be weighted by its source: it comes from the same single network, largely in uncontrolled settings, so it is reassuring anecdote rather than established safety data. The more substantive concern is mechanistic — telomerase and ALT activation are hallmarks of cancer, and the 2025 cell-line work showed cancer cells lengthening telomeres under Epitalon. A compound whose selling point is switching on telomere maintenance therefore carries an inherent oncogenic question that the longevity marketing does not address.
Epitalon is not an FDA-approved drug; it is a research compound (with some regional/clinical history in Russia tied to the pineal-peptide program). Material sold online as lyophilized "Epitalon" is unregulated, and gray-market peptide products in general show high rates of identity and purity failure, including contamination of falsified peptides with toxic elements — so the contents of any such vial are not assured.
Sources
Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells
This in vitro study by Khavinson and colleagues added the tetrapeptide Epithalon (Ala-Glu-Asp-Gly) to cultures of telomerase-negative human fetal fibroblasts and measured expression of the telomerase catalytic subunit, telomerase enzymatic activity, and telomere length. Epithalon treatment induced catalytic-subunit expression, restored telomerase activity, and produced telomere elongation, which the authors attributed to reactivation of the telomerase gene in somatic cells. They proposed this could extend the proliferative life span of the cell population. The work is a small cell-culture study from a single research group. Human efficacy and safety for Epitalon are unestablished, and much of the evidence derives from one research group.
Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity
This in vitro study by an independent UK-based group treated multiple human cell lines, breast cancer lines 21NT and BT474, normal fibroblasts (IBR.3), and mammary epithelial cells (HMEC), with Epitalon and measured telomere length, hTERT expression, telomerase activity, and markers of alternative lengthening of telomeres (ALT). Epitalon extended telomere length in normal cells primarily through upregulation of hTERT mRNA, whereas in the cancer lines telomere extension was associated mainly with ALT activation rather than telomerase. The results provide non-originating-group support for telomere effects but remain confined to cell culture, and a published correction replaced figures in the original article. Human efficacy and safety for Epitalon are unestablished, and much of the broader evidence derives from one research group.
Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice
This in vivo study administered 1 mg of Epithalon (Ala-Glu-Asp-Gly) subcutaneously five times weekly from 2 months of age until death in female HER-2/neu transgenic FVB/N mice, a strain genetically predisposed to mammary tumors, and tracked lifespan, tumor incidence, metastases, and reproductive function. Epithalon prolonged average and maximum lifespan by 13.5% (P<0.05) and 13.9% respectively, reduced lung metastases roughly 1.6-fold, decreased multiple-tumor occurrence about 2-fold, and increased the fraction of tumor-free animals about 3.7-fold. Findings come from a single transgenic mouse model studied by the originating research group. Human efficacy and safety for Epitalon are unestablished, and much of the evidence derives from one research group.
Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa
Combined animal and uncontrolled clinical report (Khavinson, Razumovsky, Trofimova and colleagues, Neuroendocrinology Letters 2002) of the synthetic tetrapeptide Epitalon (Ala-Glu-Asp-Gly) in degenerative retinal disease. In Campbell rats with hereditary retinal degeneration, epitalon intensified the retina's bioelectric and functional activity and helped preserve its morphological structure. In patients with degenerative retinal lesions, the authors reported a positive clinical effect in roughly 90% of cases. The human data are an uncontrolled clinical series from the originating research group, without randomization, blinding, or a comparison arm, and are published in a low-impact journal; they should be read as preliminary rather than confirmatory.
Peptides of pineal gland and thymus prolong human life
This long-term clinical study by Khavinson and Morozov followed 266 elderly and older persons given the thymic peptide Thymalin and/or the pineal peptide Epithalamin over a multi-year period, assessing cardiovascular, endocrine, immune, and nervous-system function, respiratory and cardiovascular disease manifestations, and mortality against an untreated comparison group. Reported mortality reductions were roughly 2.0-2.1-fold with Thymalin, 1.6-1.8-fold with Epithalamin, 2.5-fold with combined treatment, and up to 4.1-fold when combined treatment was repeated annually for 6 years. The non-randomized comparison group and single-network conduct are notable methodological limitations. Human efficacy and safety for thymalin remain unestablished, and much of the supporting evidence derives from one research group.
Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties
This narrative review consolidates roughly 25 years of in vitro, in vivo, and in silico research on Epitalon (the AEDG tetrapeptide derived from the pineal extract epithalamin), spanning antioxidant, neuroprotective, and antimutagenic mechanisms, telomerase activation and telomere elongation in cell cultures, effects on melatonin synthesis, and geroprotective and lifespan observations across cellular, invertebrate, mammalian, and primate models. The authors note that the precise mechanism of action remains uncertain and that physicochemical characterization of the peptide is limited. Much of the underlying primary literature originates from a single research network. Human efficacy and safety for Epitalon are unestablished, and much of the evidence derives from one research group.
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Independent narrative review (Mavrych, Shypilova, and Bolgova, Frontiers in Aging 2026) covering nine peptides used for healthy-aging interventions — including epitalon for telomere biology and GHK-Cu for dermal regeneration — mapped against fundamental hallmarks of aging such as telomere attrition, tissue-repair impairment, metabolic dysfunction, and hormonal decline. Drawing on systematic searches of PubMed, Scopus, and regulatory databases (FDA, WADA), the review distinguishes FDA-approved agents from non-approved compounds and concludes that peptides such as epitalon show promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation. Useful as a non-originating-group appraisal of the gerontology peptide field.
Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance
Analysis (Mendias and Awan, preprint, 2026) of 6,441 gray-market peptide samples across fourteen compounds — including ipamorelin, BPC-157, CJC-1295, GHK-Cu, PT-141, retatrutide, semaglutide, sermorelin, TB-500, tesamorelin, and tirzepatide. Applying two quality-acceptance frameworks, between 41.6% and 71.1% of samples failed to meet basic quality criteria, and about 15% showed measurable endotoxin contamination. The study quantifies how often directly-marketed "research grade" peptides miss purity and content benchmarks — a central safety concern for any non-pharmaceutical source.